Clinical Trials Logo

Clinical Trial Summary

The etiology of OSMF is considered to be multifactorial. However, Role of autoimmunity had been suggested as one of the factors but remains unproven.

The present study is undertaken to evaluate the presence of auto antibodies in OSMF patients to pave a way for new arena of treatment with the etiology of this persistent condition


Clinical Trial Description

Oral submucous fibrosis (OSMF) is a potentially malignant disorder affecting any part of the oral cavity, sometimes pharynx associated with juxta epithelial fibrosis causing progressive trismus leading to dysphagia. It is mainly seen in the Asian countries with more prevalence in India.

Etiology of OSMF is considered to be multifactorial. However, it is strongly associated with the use of arecanut in various forms and also in combination with other compounding factors. Autoimmunity had been suggested as one of the factors yet unproven.

Few studies reveal that there is high incidence of Autoantibodies including antinuclear (ANA), Anti smooth muscle (SMA), Anti thyroid microsomal (TMA), and anti reticulin antibodies in OSMF patients. These findings have not been consistent in further studies which needs further more research in this.

A study concentrated on quantitation of circulating immune complexes (CIC) levels which was established in patients with oral cancer and oral precancerous lesions. The levels were compared with that in normal controls and chronic chewers of betel quid with no signs of any disease. Both patients with oral cancer and oral precancerous lesions had elevated CIC when compared to both the control groups. The most interesting observations were (a) the CIC levels in the chewing controls were significantly raised when compared to normal controls; and (b) the CIC levels in the patients with premalignant lesions were elevated almost to the same levels as in the oral cancer patients.

HLA-typing was carried on areca nut chewers. however, it was unable to demonstrate a specific pattern of HLA-antigen frequencies in chewers with or without the disease. It is not necessarily a HLA-associated susceptibility in Oral Submucous Fibrosis.

Due to less number of articles published on autoantibodies, this study is done to evaluate the presence of such auto antibodies in OSMF patients thereby paving way for new arena of treatment on par with the etiology of this persistent condition. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03011086
Study type Observational
Source Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre
Contact
Status Completed
Phase N/A
Start date January 2015
Completion date December 2017

See also
  Status Clinical Trial Phase
Completed NCT04153266 - Oral Epithelial Dysplasia Informational Needs Questionnaire
Not yet recruiting NCT06332612 - Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial Phase 1/Phase 2
Completed NCT02711046 - Use of Single Staged Nasolabial Flap in Oral Submucous Fibrosis N/A
Recruiting NCT03511261 - Efficacy of Curcumin in Oral Submucous Fibrosis Phase 2
Completed NCT03732872 - Epithelial Mesenchymal Transition Markers in OSMF
Completed NCT04476420 - Comparative Effect of Nigella Sativa and Conventional Management for OSMF Phase 3
Active, not recruiting NCT02645656 - Topical Application of Curcumin Orabase in Oral Submucous Fibrosis (OSMF) Phase 2
Not yet recruiting NCT04487938 - Oral Cancer Screening and Education in Hong Kong